J Korean Surg Soc.  2005 Dec;69(6):488-492.

Laparoscopic Cholecystectomy in a Hemophiliac Patient with Factor VIII Inhibitor

Affiliations
  • 1Department of Surgery, Yonsei University College of Medicine, Seoul, Korea. wjlee@yumc.yonsei.ac.kr

Abstract

Hemophilia A is a severe bleeding disorder resulting from the lack of functional blood coagulation factor VIII. Accordingly, operations on patients with hemophilia A, except in a few cases, are performed with the administration of factor VIII. However, in those hemophilia A patients administered factor VIII inhibitor, factor VIII replacement therapy is ineffective. The treatment of hemophilic patients with factor VIII inhibitor is undertaken to utilize the hemostatic capacity of the activated forms of FVII, FIX and FX contained within prothrombin complex concentrates, which are purposely manufactured to contain Factor Eight Inhibitor Bypassing Activity (FEIBA) during surgery. Further, in the last few years, a new product, recombinant activated FVII (FVIIa, Novo-VII), which is thought to ensure hemostasis by binding, directly or in complex with tissue factor, to negatively charged phospholipids on the surface of activated platelets, has been licensed. Recently, we experienced a GB stone, with acute cholecystitis, in a fifty year old hemophilia A man treated with factor VIII inhibitor. Under medication with FEIBA and Novo-VII, a laparoscopic cholecystectomy was performed. Here, this case is reported, with a review of the literature.

Keyword

Hemophilia A; Factor VIII inhibitor; FEIBA; Novo-VII

MeSH Terms

Cholecystectomy, Laparoscopic*
Cholecystitis, Acute
Factor VIII*
Hemophilia A
Hemorrhage
Hemostasis
Humans
Phospholipids
Prothrombin
Thromboplastin
Factor VIII
Phospholipids
Prothrombin
Thromboplastin
Full Text Links
  • JKSS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr